Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, CNRS, UPS, 31077, Toulouse, France.
Centre de Biochimie Structurale, CBS, CNRS, INSERM, Université de Montpellier, 34090, Montpellier, France.
Sci Rep. 2021 Sep 10;11(1):18042. doi: 10.1038/s41598-021-97197-4.
Owing to their role in activating enzymes essential for bacterial viability and pathogenicity, phosphopantetheinyl transferases represent novel and attractive drug targets. In this work, we examined the inhibitory effect of the aminido-urea 8918 compound against the phosphopantetheinyl transferases PptAb from Mycobacterium abscessus and PcpS from Pseudomonas aeruginosa, two pathogenic bacteria associated with cystic fibrosis and bronchiectasis, respectively. Compound 8918 exhibits inhibitory activity against PptAb but displays no activity against PcpS in vitro, while no antimicrobial activity against Mycobacterium abscessus or Pseudomonas aeruginosa could be detected. X-ray crystallographic analysis of 8918 bound to PptAb-CoA alone and in complex with an acyl carrier protein domain in addition to the crystal structure of PcpS in complex with CoA revealed the structural basis for the inhibition mechanism of PptAb by 8918 and its ineffectiveness against PcpS. Finally, in crystallo screening of potent inhibitors from the National Cancer Institute library identified a hydroxypyrimidinethione derivative that binds PptAb. Both compounds could serve as scaffolds for the future development of phosphopantetheinyl transferases inhibitors.
由于其在激活细菌活力和致病性所必需的酶中的作用,磷酸泛酰巯基乙胺转移酶代表了新颖且有吸引力的药物靶标。在这项工作中,我们研究了氨基脲 8918 化合物对分枝杆菌磷酸泛酰巯基乙胺转移酶 PptAb 和铜绿假单胞菌磷酸泛酰巯基乙胺转移酶 PcpS 的抑制作用,这两种致病菌分别与囊性纤维化和支气管扩张症有关。化合物 8918 对 PptAb 表现出抑制活性,但在体外对 PcpS 没有活性,同时对分枝杆菌或铜绿假单胞菌没有抗菌活性。单独结合 PptAb-CoA 的 8918 的 X 射线晶体学分析以及与酰基辅酶 A 结合的酰基载体蛋白结构域的晶体结构,揭示了 8918 抑制 PptAb 的作用机制及其对 PcpS 无效的结构基础。最后,从国家癌症研究所文库的晶体筛选中鉴定出一种结合 PptAb 的羟嘧啶硫酮衍生物。这两种化合物都可以作为磷酸泛酰巯基乙胺转移酶抑制剂的未来开发的支架。